Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Halozyme Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $205 Mil.
Halozyme Therapeutics's quarterly retained earnings
declined
from Sep. 2025 ($502 Mil) to Dec. 2025 ($55 Mil) but then
increased
from Dec. 2025 ($55 Mil) to Mar. 2026 ($205 Mil).
Halozyme Therapeutics's annual retained earnings
increased
from Dec. 2023 ($91 Mil) to Dec. 2024 ($360 Mil) but then
declined
from Dec. 2024 ($360 Mil) to Dec. 2025 ($55 Mil).
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Halozyme Therapeutics Retained Earnings Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Halozyme Therapeutics (HALO) has a Retained Earnings of $205 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Retained Earnings too high?
Halozyme Therapeutics' current Retained Earnings is $205 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Retained Earnings compare to KYMR and IBRX?
Halozyme Therapeutics' Retained Earnings of $205 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Retained Earnings is $205 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.84, compared to a current price of $81.91 — trading 10.8% below its estimated fair value. The current Retained Earnings is $205 Mil. Halozyme Therapeutics' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Retained Earnings is $205 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $81.91 is trading 10.8% below its estimated GF Value™ of $91.84.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Retained Earnings: $205 Mil
GF Value™: $91.84 vs. price of $81.91 (10.8% below fair value)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score
Get the complete analysis for HALO
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
